Conditions: Alzheimer Disease
Keywords: Alzheimer's Disease
Allocation: RANDOMIZED | Intervention model: PARALLEL
Enrollment: 22
Healthy volunteers: no

Brief summary:
The trials investigates the changes of cerebral spinal fluid (CSF) soluble alpha-secretase cleaved APP (APPsα) levels under oral therapy with acitretin 30mg daily in patients with mild to moderate Alzheimer's disease (AD).The present study aims to demonstrate an enhancement of the α-secretase activity by acitretin as measured by increased CSF APPSα levels in human AD. Second, the safety and tolerability of acitretin in AD patients should be proven.

Detailed description:

Arms:
arm 1: oral, 30 mg per day, day 1-28 arm 2: oral, day 1-28

Interventions: intervention 1: Acitretin intervention 2: Placebo
Intervention descriptions: intervention 1: 30mg per day from Day 1 to Day 28 intervention 2: Placebo

Protocol document: